OPC-51803
Code | Size | Price |
---|
TAR-T28257-1mg | 1mg | £352.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28257-5mg | 5mg | £736.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28257-10mg | 10mg | £978.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28257-25mg | 25mg | £1,348.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28257-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28257-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28257-500mg | 500mg | £4,006.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
OPC-51803, a vasopressin V2 receptor agonist, is used potentially for the treatment of incontinence and nocturia.
CAS:
192514-54-8
Formula:
C26H32ClN3O2
Molecular Weight:
454.01
Pathway:
GPCR/G Protein
Purity:
0.98
SMILES:
CC(C)NC(=O)C[C@H]1CCCN(C(=O)c2ccc(cc2Cl)N2CCCC2)c2ccccc12
Target:
Vasopressin Receptor
References
1. Nakamura S, Hirano T, Tsujimae K, Aoyama M, Kondo K, Yamamura Y, Mori T, Tominaga M. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats. J Pharmacol Exp Ther. 2000 Dec;295(3):1005-11. PubMed PMID: 11082435.
2. Nakamura S, Hirano T, Yamamura Y, Itoh S, Kondo K, Mori T, Kambe T. Effects of OPC-51803, a novel, nonpeptide vasopressin V2-receptor agonist, on micturition frequency in Brattleboro and aged rats. J Pharmacol Sci. 2003 Dec;93(4):484-8. PubMed PMID: 14737021.
3. Mishra S, Liu J, Aponick A. Enantioselective Alkyne Conjugate Addition Enabled by Readily Tuned Atropisomeric P,N-Ligands. J Am Chem Soc. 2017 Feb 21. doi: 10.1021/jacs.7b00363. [Epub ahead of print] PubMed PMID: 28207253.
4. Nakamura S, Hirano T, Onogawa T, Itoh S, Hashimoto A, Yamamura Y, Kondo K, Mori T, Kambe T. Antidiuretic effects of a novel nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to dogs. J Pharmacol Sci. 2004 Apr;94(4):426-33. PubMed PMID: 15107583.